Investment Rating - The investment rating for the company is "Buy" (maintained) [2][19] Core Views - The report indicates that the company's short-term performance is impacted by policies such as centralized procurement and price reductions, but new products like overseas expansion and sequencing are expected to drive future growth [1][5] - The company reported a slight increase in revenue for 2024, with a total of 4.471 billion yuan, representing a year-on-year growth of 0.62%, while the net profit attributable to shareholders decreased by 1.89% to 1.194 billion yuan [3][5] - The report anticipates that the company's business will gradually stabilize and recover starting in 2025, following the full implementation of relevant adjustment policies [5][6] Financial Performance Summary - For 2023, the company achieved a revenue of 4.444 billion yuan, with a year-on-year growth rate of 0% [2] - The projected revenues for 2025, 2026, and 2027 are 4.789 billion yuan, 5.747 billion yuan, and 6.837 billion yuan, respectively, with growth rates of 7%, 20%, and 19% [2][5] - The net profit for 2025 is expected to be 1.251 billion yuan, reflecting a growth of 5% compared to the previous year [2][5] Cost and Profitability Analysis - The company's gross margin for 2024 was reported at 65.41%, showing a slight increase of 0.34 percentage points year-on-year [5] - The net profit margin for 2024 was 26.82%, which is a decrease of 0.73 percentage points compared to the previous year [5] - The report highlights that the company has maintained stable expense ratios, with a notable increase in R&D expenses due to investments in new products [5][6] Market Position and Future Outlook - The company is expected to face short-term pressure due to price reductions from centralized procurement policies, but it is projected to see a recovery in its business starting in 2025 [5][6] - The report emphasizes the company's commitment to innovation, with R&D expenditures increasing from 12.87% in 2022 to 16.37% in 2024, ensuring product innovation and market competitiveness [5][6] - The company has expanded its global footprint, entering over 100 countries and regions, with overseas revenue reaching 284 million yuan in 2024, a year-on-year growth of 36.25% [5][6]

Investment Rating - The report maintains a "Recommended" rating for the company [1][9]. Core Views - The company achieved a slight increase in revenue for 2024, with a total of 4.471 billion yuan, up 0.62% year-on-year, while net profit attributable to shareholders was 1.194 billion yuan, down 1.89% year-on-year [4][5]. - The company faces multiple policy impacts in the domestic in vitro diagnostics industry, leading to a slowdown in revenue growth, which is expected to continue into Q1 2025 [5]. - The company has seen robust growth in its immune diagnostics and international markets, with international revenue increasing by 36.25% year-on-year [6][9]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 4.471 billion yuan and a net profit of 1.194 billion yuan, with a gross margin of 65.36% [4][5]. - For Q1 2025, the company reported a revenue of 996 million yuan, down 8.56% year-on-year, and a net profit of 270 million yuan, down 16.76% year-on-year [4][5]. Business Segments - The immune diagnostics segment generated 2.556 billion yuan in revenue, up 2.91% year-on-year, while microbiological testing revenue was 361 million yuan, up 11.48% year-on-year [6]. - The molecular diagnostics segment saw a significant increase in revenue, reaching 35 million yuan, up 101.01% year-on-year [6]. Market Outlook - The company is expected to leverage its extensive product line to capture opportunities arising from policy changes in the domestic market [6]. - The international market is anticipated to become a new growth point, with products entering over 100 countries and regions [6][9]. Research and Development - The company has increased its R&D investment, with R&D expenses reaching 732 million yuan, accounting for 16.37% of revenue [5][8]. - New product registrations and advancements in various diagnostic fields have enhanced the company's product offerings and brand influence [8]. Future Projections - The company forecasts net profits of 1.295 billion yuan, 1.588 billion yuan, and 1.949 billion yuan for 2025, 2026, and 2027, respectively [9].

登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：603658 公司简称：安图生物 第一节 重要提示 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3、公司全体董事出席董事会会议。 4、中勤万信会计师事务所（特殊普通合伙） 为本公司出具了标准无保留意见的审计报告。 5、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司第五届董事会第四次会议审议通过的2024年度利润分配预案：经中勤万信会计师事务所（特殊普通 合伙）审计，截至2024年12月31日，公司母公司会计报表中期末未分配利润为人民币3,279,390,877.43 元。公司拟向全体股东每股派发现金红利1.26元（含税），截至2025年4月16日，公司总股本 571,424,768股，以此计算合计拟派发现金红利719,995,207.68元（含税），占报告期内合并 ...

■ 附件三： 变更募集资金投资项目情况表 单位：万元 ■ 注："本年度实现的效益"的计算口径、计算方法应与承诺效益的计算口径、计算方法一致。 证券代码：603658 证券简称：安图生物 公告编号：2025-024 郑州安图生物工程股份有限公司 关于续聘公司2025年度审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 拟续聘的会计师事务所名称：中勤万信会计师事务所（特殊普通合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 中勤万信会计师事务所（特殊普通合伙）（以下简称"中勤万信"）系2013年12月根据财政部《关于推动 大中型会计师事务所采用特殊普通合伙组织形式的暂行规定》由原中勤万信会计师事务所有限公司转制 而成的特殊普通合伙企业，2013年12月11日经北京市财政局批准同意（京财会许可〔2013〕0083号）， 2013年12月13日取得北京市工商行政管理局西城分局核发的《合伙企业营业执照》。注册地址在北京市 西城区西直门外大街112号阳光大厦10层。中勤万信具有证监会 ...

投资评级 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 安图生物(603658) 请阅读最后一页免责声明及信息披露 http://www.cindasc.com 1 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 整体经营稳健，研发加码助力长期成长 免疫业务稳健增长，24Q1 盈利能力显著提 升 疫情后业绩恢复势好，研发高投入成效初 显 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B座 邮编：100031 [Table_Title] 经营稳健，集采压力下业务韧性凸显 [Table_ReportDate] 2025 年 04 月 18 日 [Table_S 事件：2024 ummar年，公司实现营业 ...

Investment Rating - The report maintains the investment rating for the company [1] Core Views - The company is projected to experience a slight decline in revenue in 2025, with an estimated revenue of 4438.51 million yuan, down from 4471.20 million yuan in 2024, representing a decrease of 0.73% [4][7] - Net profit is expected to increase slightly to 1216.83 million yuan in 2025, reflecting a growth rate of 1.87% compared to 1194.45 million yuan in 2024 [4][7] - The gross margin is forecasted to remain stable at around 65.61% in 2025, slightly up from 65.41% in 2024 [4][7] - The company is expected to see significant revenue growth in 2026 and 2027, with projected increases of 14.45% and 12.16%, respectively [4][7] Financial Summary - Revenue projections for the company are as follows: 4471.20 million yuan in 2024, 4438.51 million yuan in 2025, 5079.98 million yuan in 2026, and 5697.50 million yuan in 2027 [4][7] - The net profit forecast shows a gradual increase from 1194.45 million yuan in 2024 to 1610.93 million yuan in 2027 [4][7] - The company's earnings per share (EPS) is expected to rise from 2.09 yuan in 2024 to 2.82 yuan in 2027 [4][7] - The price-to-earnings (P/E) ratio is projected to decrease from 20.02 in 2024 to 14.84 in 2027, indicating potential valuation improvement [4][7] Balance Sheet Overview - Total assets are expected to grow from 11875.07 million yuan in 2024 to 13594.79 million yuan in 2027 [6][7] - Current assets are projected to increase from 6542.77 million yuan in 2024 to 9562.75 million yuan in 2027 [6][7] - The company's total liabilities are forecasted to decrease from 3183.27 million yuan in 2024 to 3211.52 million yuan in 2027, indicating improved financial stability [6][7] Cash Flow Analysis - Operating cash flow is expected to rise from 1309.28 million yuan in 2024 to 2053.43 million yuan in 2027 [6][7] - The net cash increase is projected to turn positive in 2025, with an expected increase of 497.15 million yuan [6][7] - The company is anticipated to maintain a healthy cash flow position, with significant cash reserves growing from 465.37 million yuan in 2024 to 3129.50 million yuan in 2027 [6][7]

证券研究报告 公司研究 [Table_StockAndRank] 安图生物(603658) 投资评级 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 整体经营稳健，研发加码助力长期成长 免疫业务稳健增长，24Q1 盈利能力显著提 升 疫情后业绩恢复势好，研发高投入成效初 显 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B座 [Table_ReportType] 公司点评报告 ➢ 集采压力下保持稳健经营，业务韧性凸显。2024 年公司营业收入 44.71 亿元（yoy+0.62%），分业务来看，免疫诊断业务实现营收 25.56 亿元 （yoy+2.91%），在 DRG 扩面、集采等政策压力下，展现了较强的发 展韧性，微生物检测业务实现营收 3.61 亿元（yoy+11. ...

Investment Rating - The report maintains a "Recommended" rating for the company [1][9]. Core Views - The company achieved a slight increase in revenue for 2024, with total revenue of 4.471 billion yuan, up 0.62% year-on-year, while net profit attributable to shareholders was 1.194 billion yuan, down 1.89% year-on-year [4][5]. - The company faces multiple policy impacts in the domestic in vitro diagnostics industry, leading to a slowdown in revenue growth, which is expected to continue into Q1 2025 [5][9]. - The company has seen robust growth in its immune diagnostics and international markets, with international revenue increasing by 36.25% year-on-year [6][9]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 4.471 billion yuan and a net profit of 1.194 billion yuan. The revenue for Q1 2025 was 996 million yuan, down 8.56% year-on-year, with a net profit of 270 million yuan, down 16.76% year-on-year [4][5]. - The company’s gross margin for the year was 65.36%, with a stable overall expense ratio [5]. Business Segments - The immune diagnostics segment generated 2.556 billion yuan in revenue, up 2.91% year-on-year, while microbiological testing revenue was 361 million yuan, up 11.48% year-on-year. Molecular diagnostics revenue surged by 101.01% to 35 million yuan [6]. - The company has expanded its product offerings significantly, launching new series in various diagnostic fields, enhancing its brand influence [8]. Market Outlook - The report anticipates that the company will continue to leverage its extensive product line to capture market opportunities as policies evolve [6][9]. - The forecast for net profit attributable to shareholders for 2025-2027 is 1.295 billion yuan, 1.588 billion yuan, and 1.949 billion yuan, respectively, indicating a positive long-term growth outlook despite short-term pressures [9].

事件：公司发布2024年年度报告及2025年一季度报告。2024年实现营业收入44.71亿元（+0.620%），归 母净利润11.94亿元（-1.890%），扣非净利润 10.99亿元（-7.30%），经营性现金流13.09亿元 （-10.92%）。2024Q4实现营业收入10.91亿元（-9.16%），归母净利润2.38亿元（-24.72%），扣非净利 润1.68亿元（-46.25%）。2025Q1实现营业收入9.96亿元（-8.56%）归母净利润2.70亿元（-16.76%）， 扣非净利润2.57亿元（-18.19%），经营性现金流1.66亿元（-49.35%）。 业绩承压反映行业波动影响，分子及海外业务保持快速增长。1）2024年：公司全年收入基本持平，归 母净利润小幅下滑，主要是DRG/DIP支付方式改革全面推行影响检测量、IVD集采逐步落地形成价格压 力，对公司传统优势项目造成一定冲击。公司全年盈利能力保持稳定，其中毛利率为65.41% （+0.34pct），销售/管理/研发费用率分别为17.17%/4.72%/16.37%，同比-0.01pct/+0.58pct/+1.60pct。此 外，公司20 ...

安图生物（603658）2024年净利润同比下降1.89%，扣非净利润下滑7.30%，但研发投入占比高达 16.37%，创新成果显著。 2025年4月17日，安图生物发布了2024年年报。报告显示，公司2024年实现营业总收入44.71亿元，同比 增长0.62%；归属净利润为11.94亿元，同比下降1.89%；扣非净利润为10.99亿元，同比下降7.30%。尽 管公司在财务表现上有所下滑，但其在研发投入和创新领域的表现依然亮眼，研发投入占营业收入的 16.37%，显示出公司对技术创新的高度重视。 财务表现：净利润下滑，分红力度不减 2024年，安图生物的营业总收入为44.71亿元，同比增长0.62%，增速较前几年明显放缓。归属净利润为 11.94亿元，同比下降1.89%，扣非净利润为10.99亿元，同比下降7.30%。这是公司自2020年以来首次出 现净利润同比下滑的情况，反映出公司在市场竞争和成本控制方面面临一定压力。 尽管净利润下滑，安图生物的分红力度并未减弱。公司拟10派12.6元（含税），预计派现金额合计为 7.20亿元，占净利润的60.28%。这一分红比例在医药生物行业中处于较高水平，显示出公司对股 ...